356 related articles for article (PubMed ID: 35412196)
1. Targeting Angiogenic Factors for the Treatment of Medulloblastoma.
Saker Z; Rizk M; Bahmad HF; Nabha SM
Curr Treat Options Oncol; 2022 Jun; 23(6):864-886. PubMed ID: 35412196
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
3. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.
Genovesi LA; Millar A; Tolson E; Singleton M; Hassall E; Kojic M; Brighi C; Girard E; Andradas C; Kuchibhotla M; Bhuva DD; Endersby R; Gottardo NG; Bernard A; Adolphe C; Olson JM; Taylor MD; Davis MJ; Wainwright BJ
Genome Med; 2021 Jun; 13(1):103. PubMed ID: 34154646
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis: regulators and clinical applications.
Liekens S; De Clercq E; Neyts J
Biochem Pharmacol; 2001 Feb; 61(3):253-70. PubMed ID: 11172729
[TBL] [Abstract][Full Text] [Related]
5. The biologic era of childhood medulloblastoma and clues to novel therapies.
Khatua S; Zaky W
Future Oncol; 2014 Mar; 10(4):637-45. PubMed ID: 24754593
[TBL] [Abstract][Full Text] [Related]
6. TSP2 acts as a suppresser of cell invasion, migration and angiogenesis in medulloblastoma by inhibiting the Notch signaling pathway.
Pan W; Song XY; Hu QB; Zhang M; Xu XH
Brain Res; 2019 Sep; 1718():223-230. PubMed ID: 31063715
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.
Bai RY; Staedtke V; Rudin CM; Bunz F; Riggins GJ
Neuro Oncol; 2015 Apr; 17(4):545-54. PubMed ID: 25253417
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas.
Huber H; Eggert A; Janss AJ; Wiewrodt R; Zhao H; Sutton LN; Rorke LB; Phillips PC; Grotzer MA
Eur J Cancer; 2001 Nov; 37(16):2064-72. PubMed ID: 11597385
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy.
Ranieri G; Gasparini G
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Nov; 1(3):241-53. PubMed ID: 12477290
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic therapy in pediatric brain tumors: an effective strategy?
Sie M; den Dunnen WF; Hoving EW; de Bont ES
Crit Rev Oncol Hematol; 2014 Mar; 89(3):418-32. PubMed ID: 24169416
[TBL] [Abstract][Full Text] [Related]
11. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
12. Updates on Management of Adult Medulloblastoma.
Majd N; Penas-Prado M
Curr Treat Options Oncol; 2019 Jun; 20(8):64. PubMed ID: 31236711
[TBL] [Abstract][Full Text] [Related]
13. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
14. The rationale for targeted therapies in medulloblastoma.
MacDonald TJ; Aguilera D; Castellino RC
Neuro Oncol; 2014 Jan; 16(1):9-20. PubMed ID: 24305711
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.
Virág J; Kenessey I; Haberler C; Piurkó V; Bálint K; Döme B; Tímár J; Garami M; Hegedűs B
Pathol Oncol Res; 2014 Apr; 20(2):417-26. PubMed ID: 24190638
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Tumor Microenvironment to Enhance Pediatric Brain Cancer Treatment.
Batista A; Riedemann L; Vardam T; Jain RK
Cancer J; 2015; 21(4):307-13. PubMed ID: 26222083
[TBL] [Abstract][Full Text] [Related]
17. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
Eguchi R; Kawabe JI; Wakabayashi I
J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological mechanisms of angiogenesis.
Walsh DA
Adv Clin Chem; 2007; 44():187-221. PubMed ID: 17682343
[TBL] [Abstract][Full Text] [Related]
19. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
20. Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.
Fallon I; Hernando H; Almacellas-Rabaiget O; Marti-Fuster B; Spadoni C; Bigner DD; Méndez E
SLAS Discov; 2024 Mar; 29(2):100147. PubMed ID: 38355016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
